Featured Content

Thomas Marsland, MD
Vice President Integrated Community Oncology Network Former Community Representative ASCO Board of Directors

Pfizer Offers Hope For Lower-Priced Cancer Drug Combos

(Forbes) May 26, 2016 - Speaking at the UBS Healthcare Conference, Ms. Liz Barrett, Pfizer's Global President and General Manager of Oncology, hit the challenge of cancer drug pricing head on.

Commentary: Well that was clear as mud. Perhaps in reading the article and having not heard the presentation I am missing something....



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Cancer Drugs Are The Least Likely to Receive FDA Approval

(Fortune) May 26, 2016 - Oncology was the clear outlier across the 14 examined disease types when it came to the probability of a successful phase III.
read article »

Roche Boosted by Early Trial Success with Blood Cancer Drug

(Reuters) May 27, 2016 - Roche got a big boost on Friday when a clinical trial testing its new blood cancer drug Gazyva proved successful, lifting prospects for a new medicine that will be pivotal as the Swiss company fights the threat of biosimilar competition.
read article »

AstraZeneca Posts Positive Results In Cancer Trial

(MarketWatch) May 27, 2016 - AstraZeneca PLC said Friday it had positive results from the Phase III hormonal therapy trial comparing the Faslodex drug to Arimidex in the treatment of breast cancer.
read article »

NICE Turns Down Lilly's Lung Cancer Drug Portrazza

(PharmaTimes [UK]) May 27, 2016 - The National Institute for Health and Care Excellence has published draft guidelines rejecting the drug, in combination with gemcitabine and cisplatin, for treating locally advanced or metastatic epidermal growth factor receptor (EGFR)-expressing squamous non-small-cell lung cancer that has not been treated with chemotherapy.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Pfizer Offers Hope For Lower-Priced Cancer Drug Combos (Forbes)

Well that was clear as mud. Perhaps in reading the article and having not heard the presentation I am missing something....posted by: Thomas Marsland, MD

Genentech Accused Again Of Cheating Health Care Providers (STAT/Pharmalot)

Simply explained: when an oncology provider opens a package of Genentech’s Herceptin and reconstitutes the lyophilized...posted by: William Harwin MD

Proposal to Reduce Medicare Drug Payments Is Widely Criticized (New York Times)

This mandatory CMS payment experiment ignores informed consent for our patients who are forced by CMS to participate....posted by: Dean Gesme, MD

Breast Cancer Drug Rejected Despite Doubling In Tumour Destruction (The Telegraph [UK])

So this article really made me think (and that's always dangerous...) Could rationing happen here in US ??? ...posted by: Thomas Marsland, MD

Pfizer's Ibrance Delays Breast Cancer Progression: Study (Fox News/Reuters)

Pfizer's Ibrance is an extraordinary advance in the treatment of hormone sensitive metastatic breast cancer. With...posted by: William Harwin MD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.




OBR Job Board

Navigating Cancer has 1 job posted.


Bayer Pharmaceuticals has 1 job posted.


Touchpoint Solutions has over 20 jobs posted.


Check out the OBR Job Board here.





The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
CCXI +17.65%
STML +15.02%
OMED +7.66%
VRML -6.92%
GTXI -4.00%
TKMR -3.76%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: June 1, 2016
Company: Advanced Accelerator Application SA
Product: Somakit-TATA (kit for the Preparation of 68Ga-DOTATATE for Injection)

Date: June 4, 2016
Company: ARIAD Pharmaceuticals
Product: brigatinib

Date: June 5, 2016 (08:00-11:00 CDT)
Company: Roche / Genentech
Product: Atezolizumab (atezo)

See All OBR Radar items»